2020
Targeting Innate Immunity to Treat Cancer
Austin M, Kluger H. Targeting Innate Immunity to Treat Cancer. Cancers 2020, 12: 2723. PMID: 32977403, PMCID: PMC7597964, DOI: 10.3390/cancers12102723.Peer-Reviewed Original Research
2019
Transcriptomic Hallmarks of Tumor Plasticity and Stromal Interactions in Brain Metastasis
Wingrove E, Liu ZZ, Patel KD, Arnal-Estapé A, Cai WL, Melnick MA, Politi K, Monteiro C, Zhu L, Valiente M, Kluger HM, Chiang VL, Nguyen DX. Transcriptomic Hallmarks of Tumor Plasticity and Stromal Interactions in Brain Metastasis. Cell Reports 2019, 27: 1277-1292.e7. PMID: 31018140, PMCID: PMC6592283, DOI: 10.1016/j.celrep.2019.03.085.Peer-Reviewed Original ResearchConceptsBrain metastasesBrain tumor microenvironmentLineage programTumor microenvironmentTumor plasticityStromal gene expressionTranscriptomic hallmarksGene expressionTranscriptional hallmarksMultiple tumor typesMolecular landscapeStromal interactionsMajor siteIntact tissueNeuroinflammatory responseSyngeneic modelPatient biopsiesTumor typesMetastasisMalignant cellsDifferent subtypesTumor cellsHallmarkTranscriptomeCells
2015
Melanoma: Clinical Presentations
Kibbi N, Kluger H, Choi JN. Melanoma: Clinical Presentations. Cancer Treatment And Research 2015, 167: 107-129. PMID: 26601860, DOI: 10.1007/978-3-319-22539-5_4.Peer-Reviewed Original ResearchConceptsNon-cutaneous lesionsUpper gastrointestinal mucosaMalignant skin lesionsGenital mucosaUveal tractClinical presentationDistant metastasisCutaneous lesionsPattern of spreadTypical presentationGastrointestinal mucosaSkin lesionsOral cavityMucosal surfacesMalignant cellsMelanomaRed lesionsLesionsRegional spreadBasal layerMucosaMelanocytesPresentationLeptomeningesMetastasis
2012
Chapter One Vertical Pathway Targeting in Cancer Therapy
Shahbazian D, Sznol J, Kluger HM. Chapter One Vertical Pathway Targeting in Cancer Therapy. Advances In Pharmacology 2012, 65: 1-26. PMID: 22959021, DOI: 10.1016/b978-0-12-397927-8.00001-4.Peer-Reviewed Original ResearchConceptsVital cellular processesDifferent signaling pathwaysDNA maintenanceCellular processesCell divisionDrug combinationsSignaling pathwaysSame pathwayAdaptive responseParticular mutationCell proliferationRecent discoveryPathwayTypes of cancerFragile nodesAdditional targetsGrowth inhibitoryUnavoidable toxicitiesMutationsMultitarget inhibitionCytotoxic effectsCancer researchSolid tumorsProlonged responseMalignant cells
2007
Assessment of PI3 kinase as a druggable target in melanoma
Aziz S, Pick-Golan E, McCarthy M, Flaherty K, Camp R, Rimm D, Kluger H. Assessment of PI3 kinase as a druggable target in melanoma. Journal Of Clinical Oncology 2007, 25: 8521-8521. DOI: 10.1200/jco.2007.25.18_suppl.8521.Peer-Reviewed Original ResearchPI3-kinaseKinase expressionDrug targetsIntracellular signal transduction pathwaysNumerous cellular functionsSignal transduction pathwaysMajor intracellular signal transduction pathwaysPI3-kinase inhibitorAttractive drug targetValuable drug targetsCellular functionsTransduction pathwaysDifferential expressionBenign neviKinaseDruggable targetsExpression levelsProtein levelsMalignant melanocytesKinase inhibitorsDisease aggressionExpressionMalignant cellsPrimary specimensTarget